Rebecca J Hart1, Michelle D Stevenson1, Michael J Smith2, A Scott LaJoie3, Keith Cross1. 1. Division of Pediatric Emergency Medicine, Department of Pediatrics, University of Louisville, Louisville, Kentucky. 2. Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Louisville, Louisville, Kentucky. 3. Department of Health Promotion and Behavioral Sciences, School of Public Health and Information Sciences, University of Louisville, Louisville, Kentucky.
Abstract
Importance: Influenza is a significant public health burden, causing morbidity and mortality in children, yet vaccination rates remain low. Vaccination in the pediatric emergency department (PED) setting may be beneficial but, to date, has not been proven to be cost-effective. Objective: To compare the cost-effectiveness of 4 strategies for PED-based influenza vaccine: offering vaccine to all patients, only to patients younger than 5 years, only to high-risk patients (all ages), or to no patients. Design, Setting, and Participants: Using commercial decision analysis software, a cost-effectiveness analysis was performed from January 1, 2016, to June 1, 2017, to compare influenza vaccine strategies at a tertiary, urban, freestanding PED with an estimated 60 000 visits per year among a hypothetical cohort of children visiting the above PED during influenza season. Sensitivity analyses estimated the effect of uncertainties across a variety of input variables (eg, influenza prevalence, vaccine price and effectiveness, and costs of complications). Main Outcomes and Measures: The primary outcomes were cost and incremental cost-effectiveness ratio in dollars per influenza case averted. Secondary outcomes included total societal costs, hospitalizations and deaths averted, and quality-adjusted life-years gained. Results: Offering influenza vaccine to all eligible patients has the lowest cost, at $114.45 (95% CI, $55.48-$245.45) per case of influenza averted. This strategy saves $33.51 (95% CI, $18-$62) per case averted compared with no vaccination, and averages 27 fewer cases of influenza per 1000 patients. Offering vaccine to all patients resulted in 0.72 days (95% CI, 0.18-1.78 days) of quality-adjusted life-years lost, whereas offering to none resulted in 0.91 days (95% CI, 0.25-2.2 days) of quality-adjusted life-years lost. In sensitivity analyses, this strategy remains robustly cost-effective across a wide range of assumptions. In addition to being the most cost-effective strategy regardless of age or risk status, routine vaccination in the PED results in a net societal monetary benefit under many circumstances. In Monte Carlo analysis, offering vaccine to all patients was superior to other strategies in at least 99.8% of cases. Conclusions and Relevance: Although few PEDs routinely offer influenza vaccination, doing so appears to be cost-effective, with the potential to significantly reduce the economic (and patient) burden of pediatric influenza.
Importance: Influenza is a significant public health burden, causing morbidity and mortality in children, yet vaccination rates remain low. Vaccination in the pediatric emergency department (PED) setting may be beneficial but, to date, has not been proven to be cost-effective. Objective: To compare the cost-effectiveness of 4 strategies for PED-based influenza vaccine: offering vaccine to all patients, only to patients younger than 5 years, only to high-risk patients (all ages), or to no patients. Design, Setting, and Participants: Using commercial decision analysis software, a cost-effectiveness analysis was performed from January 1, 2016, to June 1, 2017, to compare influenza vaccine strategies at a tertiary, urban, freestanding PED with an estimated 60 000 visits per year among a hypothetical cohort of children visiting the above PED during influenza season. Sensitivity analyses estimated the effect of uncertainties across a variety of input variables (eg, influenza prevalence, vaccine price and effectiveness, and costs of complications). Main Outcomes and Measures: The primary outcomes were cost and incremental cost-effectiveness ratio in dollars per influenza case averted. Secondary outcomes included total societal costs, hospitalizations and deaths averted, and quality-adjusted life-years gained. Results: Offering influenza vaccine to all eligible patients has the lowest cost, at $114.45 (95% CI, $55.48-$245.45) per case of influenza averted. This strategy saves $33.51 (95% CI, $18-$62) per case averted compared with no vaccination, and averages 27 fewer cases of influenza per 1000 patients. Offering vaccine to all patients resulted in 0.72 days (95% CI, 0.18-1.78 days) of quality-adjusted life-years lost, whereas offering to none resulted in 0.91 days (95% CI, 0.25-2.2 days) of quality-adjusted life-years lost. In sensitivity analyses, this strategy remains robustly cost-effective across a wide range of assumptions. In addition to being the most cost-effective strategy regardless of age or risk status, routine vaccination in the PED results in a net societal monetary benefit under many circumstances. In Monte Carlo analysis, offering vaccine to all patients was superior to other strategies in at least 99.8% of cases. Conclusions and Relevance: Although few PEDs routinely offer influenza vaccination, doing so appears to be cost-effective, with the potential to significantly reduce the economic (and patient) burden of pediatric influenza.
Authors: Carlos G Grijalva; Yuwei Zhu; Derek J Williams; Wesley H Self; Krow Ampofo; Andrew T Pavia; Chris R Stockmann; Jonathan McCullers; Sandra R Arnold; Richard G Wunderink; Evan J Anderson; Stephen Lindstrom; Alicia M Fry; Ivo M Foppa; Lyn Finelli; Anna M Bramley; Seema Jain; Marie R Griffin; Kathryn M Edwards Journal: JAMA Date: 2015-10-13 Impact factor: 56.272
Authors: Brian W Patterson; Rahul K Khare; D Mark Courtney; Todd A Lee; Demetrios N Kyriacou Journal: Am J Emerg Med Date: 2011-09-09 Impact factor: 2.469
Authors: Tara A Lavelle; Martin I Meltzer; Achamyeleh Gebremariam; Kara Lamarand; Anthony E Fiore; Lisa A Prosser Journal: PLoS One Date: 2011-12-19 Impact factor: 3.240
Authors: Deliana Kostova; Carrie Reed; Lyn Finelli; Po-Yung Cheng; Paul M Gargiullo; David K Shay; James A Singleton; Martin I Meltzer; Peng-Jun Lu; Joseph S Bresee Journal: PLoS One Date: 2013-06-19 Impact factor: 3.240
Authors: Shannon H Baumer-Mouradian; Abigail Kleinschmidt; Ashley Servi; Brian Jaworski; Kimberly Lazarevic; Matthew Kopetsky; Mark Nimmer; Thomas Hanson; Matthew P Gray; Amy L Drendel Journal: Pediatr Qual Saf Date: 2020-07-08
Authors: Shannon H Baumer-Mouradian; Ashley Servi; Abigail Kleinschmidt; Mark Nimmer; Kimberly Lazarevic; Thomas Hanson; Jena Jastrow; Brian Jaworski; Matthew Kopetsky; Amy L Drendel Journal: Pediatr Qual Saf Date: 2021-04-05
Authors: Canada Parrish; Crystal A Phares; Tim Fredrickson; John B Lynch; Lauren K Whiteside; Herbert C Duber Journal: West J Emerg Med Date: 2022-08-19